Table 2:
Additional recent literature reporting advances in mass spectrometry-based cancer screening and diagnosis.
| Report | Disease Type | Method | Accuracy |
|---|---|---|---|
| Eberlin et al (2013) | Brain Cancer | DESI-MS | Histopathology Agreement |
| Paraskevaidi et al (2020) | Cervical Cancer | LA-REIMS | 94% Sensitivity and 83% Specificity |
| Sarbu, et al (2020) | Central Nervous System Disorders | IMS-MS/MS | Picomolar Sensitivity |
| Fan et al (2018) | Lung Cancer | Ultra high Resolution FT-MS | AUC of 0.51 – 0.85 |
| Wang et al (2018) | Lung Cancer | LC-MS/MS | 83.1% Sensitivity and 67% Specificity |
| Li et al (2021) | Lung cancer | PS-MS | 0.1 ppt sensitivity |
| Principe et al (2013) | Prostate Cancer | LC-MS/MS | Literature Validation |
| Øverbye et al (2015) | Prostate Cancer | LC-MS/MS | 100% Specificity and Sensitivity >60% |
| Sequeiros et al (2016) | Prostate Cancer | MS/MS (SRM) | Higher Sensitivity and Specificity than standard |
| Fujita et al (2017) | Prostate Cancer | LC-MS/MS (SRM/MRM) | AUC of 0.856 |
| Andreu et al (2017) | Bladder Cancer | LC-MS/MS | High Specificity, PCR comparison |
| Raimondo et al (2013) | Kidney Cancer | LC-MS/MS | AUC of 73 – 89% |
| Zhang et al (2018) | Pulmonary, Lung, Cervical, Colorectal, Bladder, Esophageal, Gastric Cancer | LC-MS/MS | AUC Ranging from 0.8747 – 0.9853 |
| Luo et al (2018) | Liver Cancer | LC-MS/MS | AUC Range of 0.807 – 0.901 and Sensitivity Range of 70-80.3% |
| Chi et al (2020) | Oral Cancer | Multiplexed LC-MS/MS (MRM) | AUC Range of 0.753 – 0.914 |